List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4294638/publications.pdf Version: 2024-02-01



VEDA KNALIDED

#	Article	IF	CITATIONS
1	Cleavage by MMPâ€13 renders VWF unable to bind to collagen but increases its platelet reactivity. Journal of Thrombosis and Haemostasis, 2020, 18, 942-954.	1.9	9
2	ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells. Scientific Reports, 2019, 9, 12540.	1.6	18
3	ADAM17-dependent proteolysis of L-selectin promotes early clonal expansion of cytotoxic T cells. Scientific Reports, 2019, 9, 5487.	1.6	12
4	MMPâ€13 binds to platelet receptors αIIbβ3 and GPVI and impairs aggregation and thrombus formation. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 370-379.	1.0	9
5	TMEFF2 shedding is regulated by oxidative stress and mediated by ADAMs and transmembrane serine proteases implicated in prostate cancer. Cell Biology International, 2018, 42, 273-280.	1.4	7
6	P2â€193: THE ROLE OF EPHA1 IN BLOODâ€BRAIN BARRIER INTEGRITY AND NEUROINFLAMMATION IN LATEâ€ON ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P743.	SET 0.4	1
7	P2X7 receptor-mediated TC2 externalization: a link to inflammatory arthritis?. Amino Acids, 2017, 49, 453-460.	1.2	9
8	P2X7 receptor activation regulates rapid unconventional export of transglutaminase-2. Journal of Cell Science, 2015, 128, 4615-28.	1.2	34
9	Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cellular Signalling, 2015, 27, 1325-1335.	1.7	26
10	The Recognition of Collagen and Triple-helical Toolkit Peptides by MMP-13. Journal of Biological Chemistry, 2014, 289, 24091-24101.	1.6	43
11	Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice. PLoS ONE, 2013, 8, e55667.	1.1	28
12	Methods for Studying Activation of Matrix Metalloproteinases. Methods in Molecular Biology, 2010, 622, 233-243.	0.4	7
13	Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: A new frontier in TIMP engineering. Protein Science, 2009, 11, 2493-2503.	3.1	29
14	Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17. Journal of Biological Chemistry, 2007, 282, 37378-37388.	1.6	36
15	Characterization of the AB Loop Region of TIMP-2. Journal of Biological Chemistry, 2006, 281, 23386-23394.	1.6	15
16	Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovascular Research, 2005, 67, 39-49.	1.8	93
17	Threonine 98, the Pivotal Residue of Tissue Inhibitor of Metalloproteinases (TIMP)-1 in Metalloproteinase Recognition. Journal of Biological Chemistry, 2004, 279, 17562-17569.	1.6	51
18	Tailoring tissue inhibitor of metalloproteinases-3 to overcome the weakening effects of the cysteine-rich domains of tumour necrosis factor-alpha converting enzyme. Biochemical Journal, 2003, 371, 369-376.	1.7	24

VERA KNAUPER

#	Article	IF	CITATIONS
19	Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochemical Journal, 2003, 372, 799-809.	1.7	52
20	Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochemical Society Symposia, 2003, 70, 65-80.	2.7	49
21	Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. Biochemical Journal, 2002, 363, 67.	1.7	10
22	Investigation of the role of Endo180/urokinase-type plasminogen activator receptor-associated protein as a collagenase 3 (matrix metalloproteinase 13) receptor. Biochemical Journal, 2002, 363, 67-72.	1.7	15
23	Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-α-converting enzyme. Biochemical Journal, 2002, 364, 227-234.	1.7	48
24	Matrix metalloproteinases in arthritic disease. Arthritis Research, 2002, 4, S39.	2.0	278
25	ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochemical and Biophysical Research Communications, 2002, 293, 501-508.	1.0	216
26	The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Letters, 2002, 520, 102-106.	1.3	33
27	The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Letters, 2002, 524, 154-158.	1.3	128
28	Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13. FEBS Letters, 2002, 532, 127-130.	1.3	102
29	Full-Length and N-TIMP-3 Display Equal Inhibitory Activities toward TNF-α Convertase. Biochemical and Biophysical Research Communications, 2001, 280, 945-950.	1.0	60
30	Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Letters, 2001, 491, 137-142.	1.3	77
31	Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Letters, 2001, 503, 158-162.	1.3	169
32	Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63ÂkDa active species. Biochemical Journal, 2001, 357, 107.	1.7	72
33	Identification and Enzymatic Characterization of Two Diverging Murine Counterparts of Human Interstitial Collagenase (MMP-1) Expressed at Sites of Embryo Implantation. Journal of Biological Chemistry, 2001, 276, 10253-10262.	1.6	166
34	The role of exon 5 in fibroblast collagenase (MMP-1) substrate specificity and inhibitor selectivity. FEBS Journal, 2001, 268, 1888-1896.	0.2	20
35	Tyrosine 36 Plays a Critical Role in the Interaction of the AB Loop of Tissue Inhibitor of Metalloproteinases-2 with Matrix Metalloproteinase-14. Journal of Biological Chemistry, 2001, 276, 32966-32970.	1.6	39
36	Characterization of the Role of the "MT-loop― Journal of Biological Chemistry, 2001, 276, 42018-42026.	1.6	68

#	Article	IF	CITATIONS
37	One-step sandwich enzyme immunoassay using monoclonal antibodies for detection of human enamelysin (MMP-20). European Journal of Oral Sciences, 2000, 108, 530-537.	0.7	7
38	Biochemical Characterization of the Catalytic Domain of Human Matrix Metalloproteinase 19. Journal of Biological Chemistry, 2000, 275, 14809-14816.	1.6	118
39	Membrane Type 4 Matrix Metalloproteinase (MMP17) Has Tumor Necrosis Factor-α Convertase Activity but Does Not Activate Pro-MMP2. Journal of Biological Chemistry, 2000, 275, 14046-14055.	1.6	195
40	Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus. Journal of Biological Chemistry, 2000, 275, 41358-41363.	1.6	112
41	An Analysis of Two Refolding Routes for a C-Terminally Truncated Human Collagenase-3 Expressed in Escherichia coli. Protein Expression and Purification, 2000, 19, 246-252.	0.6	5
42	The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Letters, 2000, 473, 275-279.	1.3	351
43	Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Letters, 2000, 478, 52-56.	1.3	110
44	Cloning and Characterization of Human MMP-23, a New Matrix Metalloproteinase Predominantly Expressed in Reproductive Tissues and Lacking Conserved Domains in Other Family Members. Journal of Biological Chemistry, 1999, 274, 4570-4576.	1.6	181
45	The Specificity of TIMP-2 for Matrix Metalloproteinases Can Be Modified by Single Amino Acid Mutations. Journal of Biological Chemistry, 1999, 274, 20391-20396.	1.6	73
46	Evaluation of Some Newer Matrix Metalloproteinases. Annals of the New York Academy of Sciences, 1999, 878, 25-39.	1.8	90
47	Inhibition of the Metalloproteinase Domain of Mouse TACE. Annals of the New York Academy of Sciences, 1999, 878, 728-731.	1.8	13
48	Mechanisms for pro matrix metalloproteinase activation. Apmis, 1999, 107, 38-44.	0.9	406
49	Phosphinic Pseudo-Tripeptides as Potent Inhibitors of Matrix Metalloproteinases:  A Structureâ^'Activity Study. Journal of Medicinal Chemistry, 1999, 42, 2610-2620.	2.9	107
50	Membrane type matrix metalloproteinases: regulators of focal proteolysis. , 1999, , 99-115.		0
51	TNF-Î \pm converting enzyme (TACE) is inhibited by TIMP-3. FEBS Letters, 1998, 435, 39-44.	1.3	547
52	Collagenase 2 (MMP-8) Expression in Murine Tissue-remodeling Processes. Journal of Biological Chemistry, 1998, 273, 23959-23968.	1.6	121
53	Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochemical Journal, 1998, 331, 453-458.	1.7	166
54	Membrane-Type Matrix Metalloproteinases and Cell Surface-Associated Activation Cascades for Matrix Metalloproteinases. , 1998, , 199-218.		36

#	Article	IF	CITATIONS
55	The Role of the C-terminal Domain of Human Collagenase-3 (MMP-13) in the Activation of Procollagenase-3, Substrate Specificity, and Tissue Inhibitor of Metalloproteinase Interaction. Journal of Biological Chemistry, 1997, 272, 7608-7616.	1.6	301
56	Limited Cleavage of Extracellular Matrix Protein BM-40 by Matrix Metalloproteinases Increases Its Affinity for Collagens. Journal of Biological Chemistry, 1997, 272, 9237-9243.	1.6	133
57	Identification and Characterization of a Novel Human Matrix Metalloproteinase with Unique Structural Characteristics, Chromosomal Location, and Tissue Distribution. Journal of Biological Chemistry, 1997, 272, 4281-4286.	1.6	207
58	Identification and Structural and Functional Characterization of Human Enamelysin (MMP-20)â€,‡. Biochemistry, 1997, 36, 15101-15108.	1.2	199
59	Relating matrix metalloproteinase structure to function: Why the "hemopexin―domain?. Matrix Biology, 1997, 15, 511-518.	1.5	294
60	Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis. FEBS Letters, 1997, 405, 60-64.	1.3	55
61	Activation of Progelatinase B (proMMP-9) by Active Collagenase-3 (MMP-13). FEBS Journal, 1997, 248, 369-373.	0.2	160
62	A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil) Tj ETQq0 0 0 rgB	T /Qverloc	k 10 Tf 50 46 46
63	Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Letters, 1996, 380, 17-20.	1.3	326
64	Biochemical Characterization of Human Collagenase-3. Journal of Biological Chemistry, 1996, 271, 1544-1550.	1.6	776
65	Activation of Human Neutrophil Procollagenase by Stromelysin 2. FEBS Journal, 1996, 235, 187-191.	0.2	57
66	Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation. Journal of Biological Chemistry, 1996, 271, 17124-17131.	1.6	644
67	Different Susceptibility of Small and Large Human Tenascin-C Isoforms to Degradation by Matrix Metalloproteinases. Journal of Biological Chemistry, 1995, 270, 8650-8654.	1.6	150
68	Neutrophil Procollagenase Can Be Activated by Stromelysin-2. Annals of the New York Academy of Sciences, 1994, 732, 367-368.	1.8	4
69	Mercurial activation of human PMN leucocyte type IV procollagenase (gelatinase). FEBS Letters, 1992, 298, 280-284.	1.3	27
70	Isolation and characterization of tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) from human rheumatoid synovial fluid. FEBS Letters, 1992, 296, 16-20.	1.3	30
71	Inactivation of human plasma C1-inhibitor by human PMN leucocyte matrix metalloproteinases. FEBS Letters, 1991, 290, 99-102.	1.3	18

72Mercurial activation of human polymorphonuclear leucocyte procollagenase. FEBS Journal, 1991, 202,
1223-1230.0.229

#	Article	IF	CITATIONS
73	Characterization and activation of procollagenase from human polymorphonuclear leucocytes. N-terminal sequence determination of the proenzyme and various proteolytically activated forms. FEBS Journal, 1990, 189, 295-300.	0.2	93
74	Addendum to Partial Amino-Acid Sequence of Human PMN Leukocyte Procollagenase. Biological Chemistry Hoppe-Seyler, 1990, 371, 733-734.	1.4	15
75	Inactivation of human plasma α1 -proteinase inhibitor by human PMN leucocyte collagenase. FEBS Letters, 1990, 263, 355-357.	1.3	64